Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.

Damante, Mark; Huntoon, Kristin; Gibbs, David; Pezzutti, Dante; Olencki, Thomas; Elder, J Bradley

Damante, Mark; Huntoon, Kristin; Gibbs, David; Pezzutti, Dante; Olencki, Thomas; Elder, J Bradley.

Affiliation

Damante M; 1Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Huntoon K; 1Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Gibbs D; 2The Ohio State University College of Medicine, Columbus, Ohio; and.
Pezzutti D; 2The Ohio State University College of Medicine, Columbus, Ohio; and.
Olencki T; 3Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Elder JB; 1Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Neurosurg Focus ; 55(2): E2, 2023 08.

Article in En | MEDLINE | ID: mdl-37527670

Subject(s)
Key words

brain metastasis; checkpoint inhibitor; molecular targeted therapy; renal cell carcinoma

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Neurosurg Focus Journal subject: NEUROCIRURGIA Year: 2023 Document type: Article Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google